C. diff Risk


Oral Bioavailability


Spectrum Of Activity


750 mg PO/IV q24h

50+ mL/min20 - 49 mL/min0 - 20 mL/min750 mg PO/IV q24h750 mg PO/IV q48h750 mg PO/IV load, then 500 mg PO/IV q48h

750 mg PO/IV load, then 500 mg PO/IV qHD

750 mg PO/IV q24h

750 mg PO/IV load, then 500 mg PO/IV q48h

General Information

Additional Information

May exacerbate muscle weakness in persons with myasthenia gravis. Avoid Use.

Adverse Effects

QTc prolongation


CNS toxicity including confusion, psychosis

Tendinopathy and rupture

GI upset

Weakness exacerbation in myasthenia gravis


Drug Monitoring

Monitor QTc in patients with increased risk

Major Interactions

Other QTc prolonging agents

Di- & Trivalent cations including Al, Ca, Fe, Mg (antacids, dairy products, iron supplements, some enteral feeds) - decreased absorption

NSAIDs - increase seizure risk

Warfarin - increased INR


Antimicrobial class: Fluoroquinolone

Pregnancy category: C